ONCAlert | Upfront Therapy for mRCC
News
Bemcentinib Achieves Efficacy in Phase II NSCLC Trial, Setting Stage for Further Enrollment
6:53 PM, Tue January 21, 2020
FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC
4:40 PM, Tue January 21, 2020
FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma
4:21 PM, Tue January 21, 2020
FDA Orphan Drug Designation Granted to Durvalumab and Tremelimumab in HCC
3:29 PM, Tue January 21, 2020
Luspatercept Reduces Anemia Severity in Lower-Risk Myeolodyplastic Syndromes
2:00 PM, Tue January 21, 2020
Olaparib Granted FDA Priority Review for HRR-Mutant mCRPC
10:00 PM, Mon January 20, 2020
Triplet Regimen Induces Clinical Benefit at 24-Month Follow-Up in BRAF-Mutant Melanoma
8:52 PM, Mon January 20, 2020
FDA Clears IND for BBT-176 in Patients with EGFR-Mutant NSCLC
5:27 PM, Mon January 20, 2020
